Ocuphire Pharma, Inc.
(NASDAQ : REXN)

( )
REXN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.74%178.190.7%$1350.94m
MRKMerck & Co., Inc. 0.21%92.610.7%$1211.55m
PFEPfizer Inc. -1.20%51.680.9%$1096.02m
LLYEli Lilly & Co. 0.74%327.131.1%$1026.00m
BMYBristol-Myers Squibb Co. -1.13%75.971.0%$991.64m
ABBVAbbVie, Inc. 0.03%153.851.9%$959.73m
AZNAstraZeneca Plc -0.67%65.511.0%$470.96m
SGENSeagen Inc. -1.85%176.775.7%$326.06m
GSKGSK Plc -1.01%43.310.2%$272.45m
TPTXTurning Point Therapeutics, Inc. 0.05%75.150.0%$199.28m
HZNPHorizon Therapeutics Plc 2.38%82.765.4%$174.09m
NVSNovartis AG -0.11%84.270.2%$172.25m
MRTXMirati Therapeutics, Inc. 1.10%71.961.6%$150.81m
ALNYAlnylam Pharmaceuticals, Inc. 1.67%150.738.1%$150.31m
NVONovo Nordisk A/S -0.40%111.190.1%$148.30m

Company Profile

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.